Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zheng-Yi ZhouJenny GriffithElla Xiaoyan DuDaniel ChinKeith A BettsArijit GanguliPublished in: Advances in therapy (2016)
AbbVie, Inc.
Keyphrases